Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Walker & Dunlop Inc is a mortgage finance business based in the US. Walker-and-Dunlop shares (WD) are listed on the NYSE and all prices are listed in US Dollars. Walker-and-Dunlop employs 999 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$127.13|
|52-week range||$56.24 - $130.35|
|50-day moving average||$114.50|
|200-day moving average||$106.04|
|Wall St. target price||$136.50|
|Dividend yield||$1.72 (1.34%)|
|Earnings per share (TTM)||$7.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-0.96%|
|1 month (2021-09-21)||17.15%|
|3 months (2021-07-21)||22.97%|
|6 months (2021-04-21)||19.43%|
|1 year (2020-10-21)||112.77%|
|2 years (2019-10-21)||108.17%|
|3 years (2018-10-19)||166.63%|
|5 years (2016-10-21)||426.85%|
Valuing Walker-and-Dunlop stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Walker-and-Dunlop's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Walker-and-Dunlop's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Walker-and-Dunlop shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Walker-and-Dunlop's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Walker-and-Dunlop's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||30.3%|
|Gross profit TTM||$1 billion|
|Return on assets TTM||6.47%|
|Return on equity TTM||21.01%|
|Market capitalisation||$4 billion|
TTM: trailing 12 months
There are currently 439,963 Walker-and-Dunlop shares held short by investors – that's known as Walker-and-Dunlop's "short interest". This figure is 20.3% down from 551,923 last month.
There are a few different ways that this level of interest in shorting Walker-and-Dunlop shares can be evaluated.
Walker-and-Dunlop's "short interest ratio" (SIR) is the quantity of Walker-and-Dunlop shares currently shorted divided by the average quantity of Walker-and-Dunlop shares traded daily (recently around 162949.25925926). Walker-and-Dunlop's SIR currently stands at 2.7. In other words for every 100,000 Walker-and-Dunlop shares traded daily on the market, roughly 2700 shares are currently held short.
However Walker-and-Dunlop's short interest can also be evaluated against the total number of Walker-and-Dunlop shares, or, against the total number of tradable Walker-and-Dunlop shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Walker-and-Dunlop's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Walker-and-Dunlop shares in existence, roughly 10 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable Walker-and-Dunlop shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Walker-and-Dunlop.
Find out more about how you can short Walker-and-Dunlop stock.
Dividend payout ratio: 23.94% of net profits
Recently Walker-and-Dunlop has paid out, on average, around 23.94% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.56% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Walker-and-Dunlop shareholders could enjoy a 1.56% return on their shares, in the form of dividend payments. In Walker-and-Dunlop's case, that would currently equate to about $1.72 per share.
While Walker-and-Dunlop's payout ratio might seem low, this can signify that Walker-and-Dunlop is investing more in its future growth.
Walker-and-Dunlop's most recent dividend payout was on 2 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2021 (the "ex-dividend date").
Over the last 12 months, Walker-and-Dunlop's shares have ranged in value from as little as $56.2368 up to $130.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Walker-and-Dunlop's is 1.2661. This would suggest that Walker-and-Dunlop's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Walker & Dunlop, Inc. , through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products and services for owners and developers of real estate in the United States. The company offers first mortgage, second trust, supplemental, construction, mezzanine, preferred equity, small-balance, and bridge/interim loans. It also provides multifamily finance for manufactured housing communities, student housing, affordable housing, and senior housing properties under the Fannie Mae's DUS program; and construction and permanent loans to developers and owners of multifamily housing, affordable housing, senior housing, and healthcare facilities. In addition, the company acts as an intermediary in the placement of commercial real estate debt between institutional sources of capital, including life insurance companies, investment banks, commercial banks, pension funds, CMBS conduits, and other institutional investors, as well as owners of various types of commercial real estate. Further, it advises on capital structure; develops the financing package; facilitates negotiations between its client and institutional sources of capital; coordinates due diligence; and assists in closing the transaction. Additionally, the company offers property sales brokerage, underwriting and risk management, and servicing and asset management services.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.